Emmessar Biotech Nutrition Ltd vs Epigral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Mar 18, 2026

Key Highlights

The Latest Trading Price of Emmessar Biotech & Nutrition Ltd is ₹ 25 as of 18 Mar 15:30 . The P/E Ratio of Emmessar Biotech & Nutrition Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Epigral Ltd changed from 16 on March 2022 to 22.9 on March 2025 . This represents a CAGR of 9.38% over 4 years The Market Cap of Emmessar Biotech & Nutrition Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Epigral Ltd changed from ₹ 4045 crore on March 2022 to ₹ 8191 crore on March 2025 . This represents a CAGR of 19.29% over 4 years The revenue of Emmessar Biotech & Nutrition Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Epigral Ltd for the Dec '25 is ₹ 602.68 crore as compare to the Sep '25 revenue of ₹ 589.1 crore. This represent the growth of 2.31% The ebitda of Emmessar Biotech & Nutrition Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Epigral Ltd for the Dec '25 is ₹ 108.26 crore as compare to the Sep '25 ebitda of ₹ 133.8 crore. This represent the decline of -19.09% The net profit of Emmessar Biotech & Nutrition Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Epigral Ltd changed from ₹ 85.87 crore to ₹ 39.11 crore over 7 quarters. This represents a CAGR of -36.20% The Dividend Payout of Emmessar Biotech & Nutrition Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Epigral Ltd changed from 5.88 % on March 2023 to 7.26 % on March 2025 . This represents a CAGR of 7.28% over 3 years .

About Emmessar Biotech & Nutrition Ltd

Emmessar Biotech & Nutrition Limited (EBNL), originally established on 17th March 1992 as Emmessar Chemical Industries Ltd (ECIL) started its operations in manufacturing Super Specialty Fine Chemicals.
The Company has so far, succeeded in developing many Specialty Fine Chemicals.
ECIL gained official recognition for its R&D from DSIR, Ministry of Science & Technology, Government of India, New-Delhi in early 1996.
To better represent its new core activity, a change in the Company name from Emmessar Chemical Industries Ltd (ECIL) to Emmessar Biotech & Nutrition Ltd (EBNL) on April 7, 2000, was made essential. On realizing that some of the specialty chemicals developed & exported to USA & Europe was being used in producing healthcare formulations, the Company plunged into a new venture in the Healthcare business, where phenomenal growth in the coming decades was anticipated.

About Epigral Ltd

Epigral Limited was erstwhile incorporated as 'Meghmani Finechem Limited' in 2007, which is engaged in manufacturing and selling of Chlor Alkali & its Derivatives and also in Trading of Agrochemical products.
The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern, through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021.
The Chlor-Alkali business commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 2020-21.
The Company is now among the leading players in India's chlor alkali industry.
In terms of the said Scheme, the Company allotted 2,39,03,029 Equity Shares of Rs 10/- each on 20th May, 2021 to the shareholders of Meghmani Organics Limited.

FAQs for the comparison of Emmessar Biotech & Nutrition Ltd and Epigral Ltd

Which company has a larger market capitalization, Emmessar Biotech & Nutrition Ltd or Epigral Ltd?

Market cap of Emmessar Biotech & Nutrition Ltd is 12 Cr while Market cap of Epigral Ltd is 3,694 Cr

What are the key factors driving the stock performance of Emmessar Biotech & Nutrition Ltd and Epigral Ltd?

The stock performance of Emmessar Biotech & Nutrition Ltd and Epigral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emmessar Biotech & Nutrition Ltd and Epigral Ltd?

As of March 18, 2026, the Emmessar Biotech & Nutrition Ltd stock price is INR ₹25.0. On the other hand, Epigral Ltd stock price is INR ₹856.45.

How do dividend payouts of Emmessar Biotech & Nutrition Ltd and Epigral Ltd compare?

To compare the dividend payouts of Emmessar Biotech & Nutrition Ltd and Epigral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.